LivaNova PLC (NASDAQ:LIVN) Receives Consensus Rating of “Moderate Buy” from Brokerages

LivaNova PLC (NASDAQ:LIVN) has been given a consensus recommendation of “Moderate Buy” by the ten ratings firms that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the company. The average 12-month target price among brokers that have covered the stock in the last year is $74.7778.

Several research analysts have recently commented on LIVN shares. Barclays raised their price objective on shares of LivaNova from $67.00 to $73.00 and gave the company an “equal weight” rating in a research note on Friday, February 27th. Weiss Ratings reiterated a “sell (d+)” rating on shares of LivaNova in a report on Monday, December 29th. Needham & Company LLC raised their price target on shares of LivaNova from $64.00 to $81.00 and gave the company a “buy” rating in a research report on Wednesday, February 25th. Stifel Nicolaus set a $80.00 price target on shares of LivaNova in a research note on Wednesday, February 25th. Finally, The Goldman Sachs Group reaffirmed a “neutral” rating and set a $66.00 price objective on shares of LivaNova in a research report on Friday, January 9th.

LivaNova Price Performance

LIVN stock opened at $62.19 on Monday. The business’s fifty day moving average price is $64.82 and its 200 day moving average price is $60.00. LivaNova has a 12-month low of $32.48 and a 12-month high of $71.92. The company has a current ratio of 1.36, a quick ratio of 1.16 and a debt-to-equity ratio of 0.29. The company has a market capitalization of $3.40 billion, a PE ratio of -13.94 and a beta of 0.92.

LivaNova (NASDAQ:LIVN) last announced its earnings results on Wednesday, February 25th. The company reported $0.86 EPS for the quarter, beating analysts’ consensus estimates of $0.80 by $0.06. The company had revenue of $360.92 million during the quarter, compared to analysts’ expectations of $354.31 million. LivaNova had a positive return on equity of 16.54% and a negative net margin of 17.46%.LivaNova’s revenue for the quarter was up 12.2% on a year-over-year basis. During the same period last year, the business posted $0.81 EPS. LivaNova has set its FY 2026 guidance at 4.150-4.250 EPS. On average, sell-side analysts anticipate that LivaNova will post 2.85 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Hantz Financial Services Inc. raised its position in LivaNova by 159.9% in the 4th quarter. Hantz Financial Services Inc. now owns 434 shares of the company’s stock valued at $27,000 after purchasing an additional 267 shares in the last quarter. State of Wyoming purchased a new position in shares of LivaNova in the 2nd quarter valued at about $31,000. EverSource Wealth Advisors LLC grew its position in shares of LivaNova by 998.4% during the second quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company’s stock worth $32,000 after buying an additional 639 shares in the last quarter. Quarry LP acquired a new position in shares of LivaNova during the third quarter worth about $36,000. Finally, UMB Bank n.a. increased its stake in shares of LivaNova by 63.0% during the third quarter. UMB Bank n.a. now owns 792 shares of the company’s stock worth $41,000 after buying an additional 306 shares during the period. 97.64% of the stock is owned by institutional investors and hedge funds.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.